Ranibizumab

• Clinical trial to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age… Pending
  2024-518990-33-00 Phase III/IV 1 country Consorci Mar Parc De Salut De Barcelona
• Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting
  2024-512298-28-00 Phase III/IV 13 countries AbbVie Deutschland GmbH & Co. KG
• Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting
  2024-516924-32-00 Phase III 9 countries F. Hoffmann-La Roche AG
• Treatment of neovascular AMD: Artificial intelligence in real-world setting Recruiting
  2024-518482-99-01 Phase IV 1 country Medical University Of Vienna
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended
  2025-520809-12-00 Phase II/III 12 countries Eyebiotech Limited
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended
  2024-510944-30-00 Phase II/III 12 countries Eyebiotech Limited
• A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan… Ended
  2023-503666-23-00 Phase III 5 countries Abbvie Deutschland GmbH & Co. KG
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended
  2023-507131-38-00 Phase III 6 countries F. Hoffmann-La Roche AG
• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended
  2023-507130-24-00 Phase III 6 countries F. Hoffmann-La Roche AG
• Long-term need of Ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due… Ended
  2023-507816-11-00 Phase III 2 countries Justus-Liebig-Universitaet Giessen
• An open-label, single group, single-dose clinical study to evaluate the usability of the pre-filled syringe (PFS) of SB11 in trial participa… Ended
  2025-520599-24-00 Phase II 1 country Samsung Bioepis Co. Ltd.
• Comparison of efficacy and safety of BP05 product and product of Lucentis in patients with Wet Age related Macular Degeneration Ended
  2023-507459-31-03 Phase III 2 countries Curateq Biologics Private Limited
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 Phase III 5 countries F. Hoffmann-La Roche AG
• A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended
  2024-512879-13-00 Phase III 10 countries Opthea Limited

Showing 1–14 of 14 trials